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On one of her visits, MB Borg, a 54 year old lady, showed 
concern about her risk of developing osteoporosis.  Lately, she 
had been listening to a series of radio and TV programmes on 
this matter where particular emphasis was put on bone density 
scans. She was preoccupied about being at risk for osteoporosis 
and wanted to know what she could do to prevent it or even treat 
it if she was found to suffer from osteoporosis.
Introduction
Osteoporosis is a systemic skeletal disorder characterized by 
decreased bone mass and deterioration of bony microarchitecture. 
The result is fragile bones and an increased risk for fracture with 
even minimal trauma. Osteoporosis is a chronic condition of 
multifactorial etiology and is usually clinically silent until a 
fracture occurs.1
Osteoporosis  affects 200 million individuals worldwide.2  In 
1990, there were 1.7 million hip fractures alone worldwide.  With 
changes in population demographics, this figure is expected to 
rise to 6 million by 2050.3  Often, osteoporosis is untreated and 
unrecognized, partially because it is a clinically silent disease 
until it manifests in the form of fracture, most commonly of 
the hip, spine and wrist.  As populations age, the number of 
osteoporotic fractures in elderly people will increase.3 
Osteoporosis creates a huge socioeconomic burden of 
disease and disability.  Identifying high-risk groups in primary 
care and using preventive treatment can result in a substantial 
reduction in morbidity and mortality.  General practitioners can 
then help by presenting a unified lifestyle message, advising on 
fall prevention and providing effective treatment.4  
Prevalence of Osteoporosis
The World Health Organization estimated the prevalence 
of osteoporosis in western women (adjusted to 1990 US white 
women) at any site as 14.8% in women aged 50-59, 21.6% for 
ages 60-69, 38.5% for ages 70-79, rising to 70.0% in women 
aged 80 or more.5 
The likelihood that any individual will suffer from an 
osteoporotic fracture is relatively high. According to a 
conservative estimate, more than one-third of adult women 
will sustain one or more osteoporotic fractures in their lifetime. 
The lifetime risk of symptomatic fracture for a 50 year old white 
woman in the UK has been estimated as 13% for the forearm, 
11% for the vertebrae and 14% for the femoral neck.6
Risk Factors for Osteoporosis
The risk factors for osteoporosis are well recognised.  The 
key risk factors for fractures (particularly hip fractures) are:
1. Previous low-trauma fracture after the age of 50 years
2. Maternal history of hip fracture
3. Low body mass index (< 19)
A large risk factor study of 7782 women aged 65 years 
and older (with a mean age of 73.3 years) identified seven 
variables: 
• Age
• BMD T-score
• Fracture after age 50 years 
• A parental history of hip fracture especially maternal hip 
fracture after age 50
• Smoking status
• Thin body type with weight less than or equal 
 to 57 kg (125 lbs)
• Use of arms to get up from a chair7
Additional risk factors for osteoporosis include:
• Being female
• Early menopause (age <45 years)
• Use of systemic corticosteroids
• Excess alcohol intake
• Hypogonadism
• Physical inactivity8
There are other secondary causes of osteoporosis that are 
shown in Table 1.
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Risk factors for low bone mass are not sufficiently sensitive 
for diagnosis or exclusion of osteoporosis.  Only bone mineral 
density (BMD) measurement can identify patients who have 
a low bone mass.  However, assessment of risk factors is 
useful for identifying women at high risk of osteoporosis, 
heightening clinical awareness of osteoporosis and developing 
societal strategies for prevention of fracture and treatment of 
osteoporosis.10  
The diagnosis of osteoporosis is based on the measurement 
of BMD. There are a number of clinical risk factors that provide 
information on fracture risk over and above that given by BMD. 
The assessment of fracture risk thus needs to be distinguished 
from diagnosis to take account of the independent value of the 
clinical risk factors.  The independent contribution of these 
risk factors can be integrated by the calculation of fracture 
probability with or without the use of BMD. Treatment can 
then be offered to those identified to have a fracture probability 
greater than an intervention threshold. 6,11
Identification of an individual’s risk profile would also form 
the basis of the decision to test for BMD.12    In a study made by 
Kanis JA et al., it was found that the most efficient assessment 
scenario was the use of clinical risk factors with the selective 
use of BMD scanning.13  The osteoporosis self-assessment tool 
(which might take the form of a questionnaire based on risk 
factor assessment) may be the most useful means for the busy 
clinician to identify postmenopausal women who would most 
benefit from BMD testing.14 
An example of such questionnaire can be viewed by linking 
to www.home.um.edu.mt/med-surg/mmj
MB could be assessed with regards to her risk of developing 
osteoporosis with an appropriately designed questionaire15 
aimed at identifying possible risk factors for osteoporosis and 
referred for bone mineral density scan accordingly.
Prevention of Osteoporosis
Independent of the bone density scan result, advice should 
be given to MB Borg by her family doctor on measures that need 
to be taken to prevent osteoporosis.
• A healthy balanced diet, rich in calcium, is crucial for strong 
and healthy bones.  Absorption of calcium from the intestine 
may be reduced by bran, bran-based cereals and chapattis. 
Urinary calcium excretion may be increased by high dietary 
intake of sodium, protein and caffeine.  Table 3 shows the 
main dietary sources of calcium.
• Vitamin D is also important to help absorb calcium from 
food. The skin can usually make enough vitamin D when 
exposed to daylight. Most people get enough from exposing 
their hands, arms and face for a few minutes a day, and 
they get that from normal daily activities – sunbathing is 
not recommended.  However, the use of sunblock creams 
prevents this effect of sunlight.  Thus, individual patients 
may need calcium and vitamin D supplements. 
• A rough guideline for patients would be that it is sensible 
to try to eat 3-4 portions of calcium a day.  Examples of a 
portion are:
•  a glass of milk (about 200ml) – as a drink on its own, on 
cereal, or in hot or cold drinks
•   a small pot of yoghurt
•   a portion (50g) of cheese or cheese spread
•   a handful of nuts or seeds
•   two slices of bread or four crackers or crisp breads
•   a serving of green vegetables (such as spinach, broccoli 
or cabbage)
•   a portion (100g) of fish with edible bones (such as tinned 
salmon or pilchards)17
• Eating a balanced diet with at least 5 portions of fruit and 
vegetables a day should ensure that the patient gets enough 
of other important nutrients too.  Examples of a portion 
are:
•   one large fruit (such as an apple, banana or pear)
•   two medium fruits (such as a satsuma, kiwi fruit or 
plum)
•   a  handful  of  small  fruit  (such as  grapes or 
strawberries)
•   one tablespoon of dried fruits
•   one small glass of fruit juice
•   two tablespoons of vegetables
•   a small bowl of salad17
• Activities such as climbing stairs, brisk walking or dancing 
– known as ‘weight-bearing’ exercise – help make bones 
stronger. Doing 30 minutes five days a week is ideal, but 
every little bit helps. Certain exercises also help the patient’s 
balance, making it less likely for them to fall. Keeping active 
is also good for the rest of the body, such as the heart and 
circulation.
Table 1:  Secondary Causes of Osteoporosis
Endocrine Nutritional Drugs Others
Thyrotoxicosis Inflammatory Bowel Disease Long-term Corticosteroid Use Rheumatoid arthritis
Cushing’s Syndrome Chronic Liver Disease Phenytoin Multiple Myeloma
Hyperprolactinaemia Coeliac Disease Phenobarbitone Metastatic Carcinoma
Hyperparathyroidism Anorexia Nervosa Overtreatment with Thyroxine Renal Disease
Hypogonadism  Vitamin D Deficiency Diuretics such as Bendrofluazide
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• It is advisable to maintain a good posture by keeping the 
head held high, chin in, shoulders back, upper back flat and 
lower spine arched.  This helps avoid stress on the spine. 
When sitting or driving, a rolled towel should be placed in 
the small of the back.  While reading or doing handwork, 
leaning over should be avoided. When lifting, bending 
should be done at the knees, and not at the waist.  Then, 
lifting should be done with the legs, keeping the upper back 
straight. 
• Smoking increases the risk of osteoporosis so the patient 
should be advised to quit if she smokes. 
• Sensible drinking doesn’t seem to increase the chance 
of developing thin bones, but long-term heavy drinking 
might.18,19 For this and other reasons, it’s not wise for women 
to drink more than 14 units of alcohol per week (no more 
than 2–3 units per day), or for men to drink more than 21 
units per week (no more than 3–4 per day).  Typically, a 
175ml glass of wine or a pint of ordinary strength beer is 
about 2 units, and a measure of spirits is one unit.
Treatment for Osteoporosis
Having established that those at highest risk of osteoporotic 
fractures should be targeted for treatment, this should be 
preceded by assessment of BMD by DEXA scan in the vast 
majority of cases.  People with two or more vertebral fractures 
(including painless fractures) are considered to be at such high 
risk of further fracture that treatment can be started without 
measuring BMD.9  The goals of treating osteoporosis are:
•  To prevent fractures
•  To stabilize or achieve an increase in bone mass
•  To relieve symptoms of fractures and skeletal deformity
•  To maximize physical function.
Treatment should include:
1. Lifestyle and nutritional advice (as described before) 
2. Drug therapy
3. Assessment and management of risk of falls, particularly in 
the elderly
Drug Treatment Options
There are a range of drug treatment options.  Guidance on 
the preferred options changes regularly with the identification 
of new treatment modalities, and the discovery of adverse 
effects of existing medications.  The current UK guidelines are 
summarised in Table 2.
The most commonly used options for which there is good 
evidence are detailed below.
• Hormone Replacement Therapy (HRT)
 HRT stops bone loss in early, late and elderly postmenopausal 
women by inhibition of bone resorption resulting in a 5-10% 
increase in BMD over 1-3 years.20  When HRT is stopped 
bone loss resumes at the same rate as after the menopause. 
The results of a meta-analysis of 13 randomised placebo-
controlled trials of HRT use suggest a 33% reduction in 
vertebral fracture21. A meta-analysis of 22 randomised 
trials of HRT use suggested a 27% reduction in non-vertebral 
fractures in a pooled analysis, with a 40% reduction for hip 
and wrist fractures.21
  HRT was the treatment of  choice in early 
postmenopausal women (within 5 years of the onset of 
the menopause) until recently.  While recent RCTs22,23 
confirm the benefit of HRT in prevention and treatment 
of osteoporosis, concerns about the balance of risks and 
benefits have led the Medicines Boards in Europe to 
recommend that HRT should be used  for the shortest 
possible time and no longer recommend it as first choice 
for the prevention of osteoporosis.
• Bisphosphonates
 The bisphosphonates are synthetic pyrophosphate 
analogues which bind strongly to hydroxyapatite crystals 
of bone and are retained in the bone for a lengthy period. 
During the process of resorption they are released locally 
and taken up by osteoclasts thereby inhibiting their ability 
to resorb bone. The commonest drugs used are etidronate, 
alendronate and risedronate.
  Etidronate is given in a cyclical pattern with the 
regimen beginning with 14 days therapy of etidronate 
400mg daily taken two hours before and two hours after 
food, followed by 76 days of calcium carbonate 500mg. 
However, it reduces the risk of vertebral fracture only.9
Treatment options Notes
First-line treatment
Alendronate Risendronate
or risendronate not licensed for use in men
 Do not use bisphosphonates in
 people who are unable to adhere
 to dosing instructions
Second-line treatment
Raloxifene, calcitonin Recommended for treatment
 or cyclical etidronate of diagnosed OP in
HRT postmenopausal women  
Calcium and Vitamin D HRT should be used for those
 in whom benefits outweigh risks
 Calcium and vitamin D may be
 used alone in elderly (80+), 
 frail or housebound
Adjunct treatment
Calcium and Vitamin D Consider as adjunct treatment
 if dietary intake suboptimal.
 Dose will depend on 
 dietary intake
Table 2:  Treatment options for osteoporosis9
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Table 3:  Composition and serving size 
of calcium containing foods16
Food  Serving  Calcium
 size per serving
   (mg)
Milk 1 cup 290-300
Cheddar/other hard cheese 1 oz 220
Yogurt 1 cup 240-400
Ice cream 1/2 cup 90-100
Cottage cheese 1/2 cup 80-100
Parmesan cheese 1 tbsp 70
Powdered non-fat milk 1 tsp 50
Sardines in oil (with bones) 3oz 370
Canned salmon (with bones) 3oz 170-210
Broccoli 1 cup 160-180
Egg 1 medium 55
Calcium-fortified food 1 serving Varies
Baked beans 4 oz 45
Dried apricots 2 oz 52
  Alendronate differs from etidronate in that the dosage 
needed to inhibit resorption is much lower and therefore it 
can be given continuously. A dose of 10mg per day is usually 
used although 70mg once weekly has a good safety profile 
and the same efficacy as 10mg daily in increasing BMD and 
reducing bone turnover.  In one randomised controlled trial 
of alendronate versus placebo, alendronate resulted in a 
BMD increase of 8.8% in vertebrae and 6.9% in the femoral 
neck and reduced all fractures from 18 to 13%.24 Another 
randomised controlled trial of alendronate plus calcium 
versus calcium and placebo showed a 48% decrease in new 
vertebral fractures, a decrease in the progression of vertebral 
deformities and a significant reduction in height loss.24  A 
further multicentred randomised controlled trial of more 
than 2,000 women followed for three years showed that 
alendronate increased average BMD while halving the rate of 
vertebral fractures.24 The FIT trial showed that alendronate 
reduced the relative risk of hip fracture by 50% in women 
with established osteoporosis.25   Thus, alendronate reduces 
the risk of both vertebral and non-vertebral fractures.9
  Risedronate prevents postmenopausal bone loss. 
In one study of 2,400 patients with vertebral fractures it 
reduced the cumulative incidence of patients with new 
vertebral fracture by 41% over three years and by 65% after 
the first year.21 It is taken at a dose of 5mg per day.  There 
is evidence that it reduces the risk of both vertebral and 
non-vertebral fractures.9
  The commonest side-effects of bisphosphonates are 
gastrointestinal disturbance causing nausea, constipation 
and diarrhoea. Oesophageal erosion, inflammation and 
ulceration can also occur. These drugs must be taken on 
an empty stomach with a minimum of 200mls of water 
on awakening, at least half an hour before food, drink and 
other medications. The patient should not lie down for at 
least 30 minutes after taking these agents. Hypocalcaemia 
and other disturbances of calcium metabolism must be 
corrected before any bisphosphonate therapy is initiated. 
Bisphosphonates are particularly useful for the treatment 
of older postmenopausal women.  
• Selective Oestrogen Receptor Modulators 
(SERMS)
  SERMS act as oestrogen agonists or antagonists 
depending on the target tissue.  
  Tamoxifen (first generation SERM) is an oestrogen 
antagonist in breast tissue but a partial agonist in bone and 
cholesterol metabolism and the endometrium. Because of 
its side effects, including increased risk of thromboembolic 
disease and hepatic and endometrial tumours, it is not used 
for the prevention or treatment of osteoporosis.
  Raloxifene (second generation SERM) has a tissue 
specific effect and competitively inhibits the action of 
oestrogen in the breast and the endometrium while acting 
as an oestrogen agonist on bone and lipid metabolism. The 
MORE (Multiple Outcomes of Raloxifene Evaluation) study, 
a three year randomised controlled trial of raloxifene use 
in more than 6,800 women, showed a decreased the risk 
of vertebral fracture by 50% at 60 or 120mg/day.26  The 
risk of non-vertebral fractures was unchanged. Raloxifene 
increased BMD at the femoral neck by 2.1 to 2.6% yearly. 
Unfortunately it was also shown to increase the risk of 
DVT.26   The ongoing RUTH study will ascertain whether 
or not the decrease in LDL cholesterol and fibrinogen seen 
in individuals taking raloxifene can result in a reduction 
in coronary heart disease in the high-risk population of 
postmenopausal women. 
  SERMS may be most useful in the treatment of older 
postmenopausal women. In younger women they can cause 
menopausal symptoms like flushing and sweating.
• Calcium and Vitamin D27
  Calcium alone: Calcium intake is important for the 
maintenance of bone mass.  Dietary supplementation of 
calcium is inexpensive and may increase BMD up to 1% over 
two years. Postmenopausal women need 1 – 1.5g elemental 
calcium daily. Ideally, calcium intake should be via ingestion 
of calcium rich foods (see Table 3). Supplementation should 
take dietary intake into account. Gastrointestinal side effects 
are mainly reported such as constipation and diarrhoea. 
Hypercalcuria is rare at dosages of less than 2g/day.
  A meta-analysis of 16 observational studies involving 
over 38,000 postmenopausal women with a mean age 
of 60-80 years, with a mean dietary calcium intake of 
 168-786mg/day showed that for every 300mg/day increase 
in dietary calcium intake there was a 4% fall in the odds 
of experiencing a hip fracture. However, four small 
randomised controlled trials involving 531 postmenopausal 
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women provided conflicting evidence on whether calcium 
alone had a protective effect against fractures.
 
 Vitamin D alone
 Vitamin D increases calcium absorption in the GI tract. 
Data from one randomized controlled trial involving 2,564 
men and women with either age-related or postmenopausal 
osteoporosis using daily oral supplements of vitamin D3 
400IU alone for 3 years had no protective effect against hip 
or any other non-vertebral fracture.
 
 Calcium plus vitamin D
 One randomized controlled trial of 2,790 elderly women 
(mean age 84 years) with age-related or postmenopausal 
osteoporosis showed that daily oral supplements of calcium 
1.2g plus vitamin D3 800 IU for 3 years helped prevent hip 
and non-vertebral fractures.  Another randomized placebo-
controlled study involving 445 younger ambulant men 
and women (average age 71 years) taking oral supplement 
of calcium 500mg plus vitamin D3 700 IU for 3 years 
reduced the incidence of non-vertebral fractures.  Combined 
calcium and vitamin D is the treatment of choice in elderly, 
housebound patients and is usually well tolerated and can 
be given indefinitely.
• Calcitonin
 Calcitonin is a peptide hormone synthesised and secreted by 
the C-cells of the thyroid. It has a direct action on osteoclasts 
thus inhibiting bone resorption. Treatment with calcitonin 
causes a short-term decrease in bone resorption. The 
usual dose is 100 IU calcitonin salmon preparation either 
intramuscularly or subcutaneously three times per week. 
Calcitonin may also possess analgesic properties and may 
be of additional benefit to patients with acute or chronic 
pain due to osteoporosis.28 
  The PROOF (Prevent Recurrences of Osteoporotic 
Fractures) study, a 5 year double blind randomised placebo 
controlled study of 1255 postmenopausal women with 
osteoporosis showed that intranasal salmon calcitonin 200 
IU per day seemed to reduce the rate of vertebral but not 
peripheral fractures by about 30% compared with placebo.29 
Unfortunately a large percentage of the study participants 
were lost to follow up.  The main adverse reactions include 
nausea, vomiting, tingling of hands and facial flushing.  Its 
use is limited due to its high cost.
• Strontium ranelate
 Strontium ranelate is a new first-line therapy recently 
licensed in Europe. It is indicated in the treatment of 
postmenopausal osteoporosis, to reduce the risk of vertebral 
and hip fractures in patients with or without a previous 
history of fractures.30  It is the first antiosteoporotic 
treatment to simultaneously increase bone formation and 
decrease bone resorption.  It increases bone formation in 
bone tissue culture as well as osteoblast precursor replication 
and collagen synthesis in bone cell culture.   It reduces bone 
resorption by decreasing osteoclast differentiation and 
resorbing activity.  This rebalances bone turnover in favor 
of the formation of new and stronger bone and provides 
early and sustained antifracture efficacy.30-33 
  Results from phase III clinical development have 
shown that strontium ranelate is effective at all major 
osteoporotic sites, including the vertebrae and hip, however 
over 3 years of treatment. In the TROPOS study, it was 
shown that strontium ranelate increased femoral neck 
bone mineral density by 8.2% after 3 years.  It also reduced 
the relative risk of nonvertebral fracture by 16% (P=0.04) 
over 3 years compared with placebo34.  It is also effective 
regardless of the severity of patient’s disease, whether 
they have osteoporosis or osteopenia and whether or not 
they have a previous fracture. Strontium ranelate is the 
first antiosteoporotic agent to show conclusive efficacy in 
patients 80 years of age and over. 30  The combined effects 
of strontium distribution in bone and increased X-ray 
absorption of strontium as compared to calcium, leads to an 
amplification of BMD measurement by DEXA scans.  Thus, 
care must be taken when interpreting BMD changes during 
treatment. 
• Teriparatide 
 Endogenous 84-amino-acid parathyroid hormone (PTH) is 
the primary regulator of calcium and phosphate metabolism 
in bone and kidney. Physiological actions of PTH include 
stimulation of bone formation by direct effects on osteoblasts 
indirectly increasing the intestinal absorption of calcium and 
increasing the tubular re-absorption of calcium and excretion 
of phosphate by the kidney.  Teriparatide is identical to the 
 34 N-terminal amino acid sequence of endogenous human 
parathyroid hormone.  This can be used in the treatment 
of established osteoporosis in postmenopausal women who 
are at high risk for having a fracture.35 However, it has been 
shown to bring about a significant reduction in the incidence 
of vertebral, but not hip, fractures. The drug is also approved 
to increase bone mass in men with primary or hypogonadal 
osteoporosis who are at high risk for fracture.  This product 
is usually used when the patient is resistant to other anti-
osteoporotic treatments.
Conclusion
As seen in the presented case, the family doctor is in the best 
position to provide information on prevention and treatment of 
osteoporosis.  Moreover, the family doctor plays a major role in 
identifying patients at high risk of developing osteoporosis and 
directing management accordingly.
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